All > Oregon > Washington

Rituximab for Diffuse Large B-cell Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Diffuse Large B-cell LymphomaRituximab - Drug
Eligibility
65+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it is effective and safe in patients with a specific type of cancer who are either unfit or frail.

Eligible Conditions
  • Diffuse Large B-cell Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Loncastuximab Tesirine
1
Rituximab
1
rituximab and lenalidomide

Study Objectives

4 Primary · 12 Secondary · Reporting Duration: Up to 5.5 years

Week 22
Number of Participants with a Change from Baseline in Patient-reported Outcomes
Number of Participants with a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score
Up to 12 weeks
Cohort B, Part 1: Percentage of Participants Completing 4 Cycles of Treatment
Cohort B: Percentage of Participants Completing 4 Cycles of Treatment
Up to 2 years
2-year Progression-free Survival (PFS)
Cohort A, Part 1: 2-years PFS
Cohorts A and B, Part 2: 2-year Progression Free Survival (PFS)
Number of Participants with Confirmed Positive Anti-Drug Antibody (ADA) Responses
Serum Concentration of Loncastuximab Tesirine Pyrrolobenzodiazepine (PBD)-conjugated Antibody
Serum Concentration of SG3199 Unconjugated Warhead
Serum Concentration of Total Antibody
Up to 22 weeks
Overall Response Rate (ORR)
Up to 3 years
3-year Overall Survival (OS)
Up to 5.5 years
CR Rate
Duration of Response (DoR)
Number of Participants who Experience a Treatment-emergent Adverse Event

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Loncastuximab Tesirine
1
Rituximab
1
rituximab and lenalidomide

Side Effects for

Rituximab
8%Mild/moderate allergic reactions
3%Severe allergic reaction
This histogram enumerates side effects from a completed 2016 Phase 2 & 3 trial (NCT03002038) in the Rituximab ARM group. Side effects include: Mild/moderate allergic reactions with 8%, Severe allergic reaction with 3%.

Trial Design

6 Treatment Groups

Cohort A, Part 2: R-mini-CHOP
1 of 6
Cohort B : Loncastuximab Tesirine + Rituximab (Lonca-R)
1 of 6
Cohort B, Part 1 and Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)
1 of 6
Cohort A, Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)
1 of 6
Cohort A, Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)
1 of 6
Cohort A : Loncastuximab Tesirine + Rituximab (Lonca-R)
1 of 6

Active Control

Experimental Treatment

80 Total Participants · 6 Treatment Groups

Primary Treatment: Rituximab · No Placebo Group · Phase 2

Cohort B : Loncastuximab Tesirine + Rituximab (Lonca-R)Experimental Group · 2 Interventions: Loncastuximab Tesirine, Rituximab · Intervention Types: Drug, Drug
Cohort B, Part 1 and Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)Experimental Group · 2 Interventions: Loncastuximab Tesirine, Rituximab · Intervention Types: Drug, Drug
Cohort A, Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)Experimental Group · 2 Interventions: Loncastuximab Tesirine, Rituximab · Intervention Types: Drug, Drug
Cohort A, Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)Experimental Group · 2 Interventions: Loncastuximab Tesirine, Rituximab · Intervention Types: Drug, Drug
Cohort A : Loncastuximab Tesirine + Rituximab (Lonca-R)Experimental Group · 2 Interventions: Loncastuximab Tesirine, Rituximab · Intervention Types: Drug, Drug
Cohort A, Part 2: R-mini-CHOPActiveComparator Group · 5 Interventions: Cyclophosphamide, Prednisone, Vincristine, Doxorubicin, Rituximab · Intervention Types: Drug, Drug, Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Loncastuximab tesirine
FDA approved
Rituximab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5.5 years

Who is running the clinical trial?

ADC Therapeutics S.A.Lead Sponsor
25 Previous Clinical Trials
1,868 Total Patients Enrolled

Eligibility Criteria

Age 65+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a pathologic diagnosis of DLBCL, as defined by the 2016 WHO classification (including participants with DLBCL transformed from indolent lymphoma), or HGBCL, or Grade 3b FL.
You have a disease or condition that is measurable by the 2014 Lugano Classification.
ANC > 1.0 x 10^3/µL (off growth factors at least 72 hours).
Platelet count ≥75 x 10^3/µL without transfusion in the past 7 days.
You have a total bilirubin level of ≤1.5 x ULN.
Creatinine clearance >30 mL/min.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top